{"filings":[{"id":95001,"accession_number":"0001723128-26-000019","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amneal Q1 2026 net revenue $723M (+4% YoY), GAAP net income $62M, adj. diluted EPS $0.27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $723M (+4% YoY); GAAP net income $62M vs. $12M in Q1 2025; diluted EPS $0.19.","Adjusted EBITDA $202M (+19% YoY); adjusted diluted EPS $0.27 (+29% vs. $0.21).","Specialty revenue +23% driven by CREXONT, BREKIYA autoinjector, and UNITHROID; Affordable Medicines +2%.","AvKARE revenue -4% as government channel growth offset decline in low-margin distribution.","Affirms previously announced increase in full year 2026 guidance; results matched preliminary numbers from April 22."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":722519000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95000,"accession_number":"0001628280-26-032137","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal shareholders approve all proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Chintu Patel received ~270.4M votes (highest).","Advisory say-on-pay passed with ~96.5% support (269.1M for, 2.58M against).","Ernst & Young LLP ratified as auditor for fiscal 2026 with 293.2M votes for.","Broker non-votes on director election and say-on-pay totaled 21.95M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94999,"accession_number":"0001193125-26-168231","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Amneal acquires Kashiv BioSciences for $750M upfront; raises FY2026 guidance on strong Q1","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Kashiv: $375M cash + $375M equity (28.9M shares) at close; up to $350M regulatory milestones plus royalties.","Expected close H2 2026; subject to shareholder and regulatory approvals; creates global biosimilar platform.","Preliminary Q1 2026 results strong; standalone FY2026 guidance raised (details per press release).","Transaction expected to deliver $400M-$500M in financial benefits; minimal impact on leverage.","Restrictive covenants agreements with co-CEOs Chirag and Chintu Patel from closing through fifth anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107765,"accession_number":"0001723128-26-000008","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal reports Q4 2025 net revenue $814M (+11% YoY); FY25 rev $3.02B; 2026 guidance $3.05-$3.15B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue $814M (+11% YoY); GAAP net income $35M; diluted EPS $0.11.","Full year 2025 net revenue $3.02B (+8% YoY); GAAP net income $72M; diluted EPS $0.22.","Adjusted EBITDA FY25 $688M (+10% YoY); Q4 adj EBITDA $175M.","FY25 adj diluted EPS $0.83 vs $0.58 prior year; Q4 adj EPS $0.21 vs $0.12.","2026 guidance: net revenue $3.05-$3.15B, adj EBITDA $720-$760M, adj EPS $0.93-$1.03."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":3018760000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107764,"accession_number":"0001628280-26-004738","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Amneal reprices $2.1B term loan, margin cut 50 bps, saving ~$11M/year","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repricing amendment reduces interest rate margin by 50 bps to SOFR+3.00% or Base Rate+2.00%.","Total Amendment No. 2 Term Loans of ~$2.095B, including ~$134.7M new term loan.","Annualized cash interest savings estimated at ~$11 million.","Maturity unchanged at August 1, 2032.","Proceeds used to refinance existing Amendment No. 1 Term Loans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107763,"accession_number":"0001628280-26-003842","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amneal Pharmaceuticals makes effective opioid settlement with states and subdivisions","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Amneal determined to make effective its Nationwide Opioids Settlement Agreement on Jan 29, 2026, with sufficient state and subdivision participation.","Company will pay $88.5 million to participating states and subdivisions.","Company will provide up to $177.4 million in naloxone nasal spray (valued at $125 per twin pack) to treat opioid overdoses.","Settling parties can opt for cash up to $44.4 million (25% of product value) during last four years of ten-year term, potentially raising total cash to $132.9 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107762,"accession_number":"0001723128-26-000003","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Amneal expects to meet or exceed FY2025 guidance; net leverage improves to 3.6x","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue guidance $3.0B-$3.1B; Adj EBITDA $675M-$685M; Adj diluted EPS $0.75-$0.80.","Operating cash flow guided at $300M-$330M; capex ~$100M","Net leverage estimated at 3.6x as of Dec 31, 2025, down from 3.9x at Dec 31, 2024.","Company reaffirms guidance originally provided on Oct 30, 2025; expects to meet or exceed targets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":3018760000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124145,"accession_number":"0001723128-25-000059","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.","Adjusted EBITDA $160M (+1% YoY); adjusted diluted EPS $0.17 (+6% YoY from $0.16).","Specialty +8% driven by CREXONT and UNITHROID; Affordable Medicines +8%; AvKARE +24%.","Incurred $22.5M milestone for XOLAIR biosimilar BLA submission; updated FY2025 guidance.","Launched BREKIYA autoinjector for migraine in October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2204441000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140820,"accession_number":"0001723128-25-000037","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.","Adjusted EBITDA $184M (+13%); adjusted diluted EPS $0.25 (+56% from $0.16).","Specialty revenue +23% driven by CREXONT, RYTARY, UNITHROID; Affordable Medicines +1%.","Raising full-year 2025 guidance; completed oversubscribed debt refinancing extending maturities to 2032.","FDA approved Brekiya autoinjector for migraine; strong CREXONT Parkinson's uptake."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1419928000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140815,"accession_number":"0001723128-25-000040","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K/A","filed_at":"2025-08-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal board adopts annual say-on-pay votes following stockholder preference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders recommended annual frequency for advisory say-on-pay votes; board agreed on August 5, 2025.","Future say-on-pay votes will be held annually until next frequency vote, due no later than 2031 annual meeting.","Amendment corrects cover-page date of original 8-K filed May 8, 2025 to May 6, 2025.","No other changes to original; matter is non-binding advisory vote on executive compensation frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140819,"accession_number":"0000950103-25-009701","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.","Issued $600M 6.875% senior secured notes due Aug 2032; proceeds used to refinance existing debt.","Amended ABL facility extends maturity to Aug 2030; $600M revolving commitments unchanged.","Refinanced existing $2.26B term loans in full and repaid all ABL borrowings with net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140818,"accession_number":"0000950103-25-009253","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amneal prices $600M 6.875% senior secured notes due 2032, upsizes term loan to $2.1B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M notes priced at par with 6.875% coupon, due 2032; downsized from $750M due to term loan increase.","New term B loans upsized to $2.1B from $1.8B, seven-year maturity.","Proceeds to refinance existing term B loans in full and repay ABL facility.","Closing expected August 1, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140817,"accession_number":"0001723128-25-000033","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Amneal prelim Q2 revenue $720M-$730M, adj EBITDA $180M-$185M; director resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $720M-$730M (+3% YoY); income before taxes $45M-$56M vs $20M in Q2 2024.","Adjusted EBITDA $180M-$185M (+13% YoY); gross leverage 3.8x, net leverage 3.7x.","Director Emily Peterson Alva resigned July 16 after Amneal Group ownership dropped below majority of Class A common stock.","Brekiya autoinjector approved for migraine/cluster headache; CREXONT uptake strong; biosimilar to XOLAIR BLA expected Q4 2025.","Full year 2025 guidance expected to be met or exceeded based on year-to-date performance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1419928000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140816,"accession_number":"0000950103-25-009025","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amneal seeks $1.8B new term loans and $750M notes to refinance debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amneal subsidiary seeks $1.8B in new seven-year term B loans to refinance existing term loans.","Launching $750M private offering of senior secured notes due 2032.","Proceeds to repay existing term B loans in full and a portion of ABL borrowings.","Notes offering not conditioned on the new term loan facility.","Transactions subject to market conditions; no assurance of completion or final terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158557,"accession_number":"0001723128-25-000024","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"All Amneal director nominees elected, say-on-pay approved at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["11 directors elected with overwhelming support; Paul Meister received lowest 'For' count at 239.8M shares.","Advisory vote on executive compensation passed with 258.8M votes for vs 1.3M against.","Stockholders selected 1 year as frequency for future say-on-pay votes (255.1M votes for 1 year).","Ratification of Ernst & Young as auditor for FY2025 approved with 289.0M votes for, 0.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158556,"accession_number":"0001723128-25-000018","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).","Adjusted EBITDA $170M (+12% YoY); adjusted diluted EPS $0.21 (+50% from $0.14).","Affordable Medicines +6%, Specialty +3%, AvKARE +6%; CREXONT and injectable momentum cited.","Company reaffirms 2025 full-year guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":695420000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176949,"accession_number":"0001723128-25-000014","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amneal promotes Jason Daly to EVP, Chief Legal Officer; base salary $575k","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Promoted from SVP to EVP, Chief Legal Officer & Corporate Secretary, effective March 1, 2025.","Employment agreement includes initial term through March 31, 2027, with auto-renewal.","Annual base salary of $575,000; bonus target 55% of base with performance multiplier 0-150%.","Severance: 150% of salary, prorated bonus, 18-month benefits, and 12-month outplacement.","Change-in-control protection: equity vesting acceleration and extended exercisability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176948,"accession_number":"0001723128-25-000009","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal reports Q4 revenue $731M (+18% YoY), FY24 revenue $2.79B (+17%); guides FY25 $3.0-3.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 GAAP net loss $31M ($0.10 diluted loss per share); adjusted net income $40M, adjusted EBITDA $155M.","Full year 2024 net revenue $2.79B (+17% YoY); GAAP net loss $117M; adjusted EBITDA $627M (+12% YoY).","All three segments (Affordable Medicines, AvKARE, Specialty) grew double-digits in FY24; CREXONT launched successfully.","FY25 guidance: net revenue $3.0-$3.1B, adjusted EBITDA $650-$675M; net leverage reduced to 3.9x a year ahead of target."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":2793957000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176947,"accession_number":"0001723128-25-000005","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).","Expects to exceed operating cash flow guidance ($280-320M) and capital expenditure guidance ($60-70M).","Estimates net leverage at approximately 4x as of December 31, 2024.","Guidance includes 100% of AvKARE EBITDA; adjusted EPS accounts for 35% non-controlling interest."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":2793957000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193742,"accession_number":"0001723128-24-000044","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K/A","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.","Adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.","Generics +9%, Specialty +19% driven by CREXONT/ONGENTYS launches; AvKARE +21%.","Affirms full-year 2024 guidance; launched CREXONT, collaboration with Metsera, in-licensed biosimilar.","Higher interest expense drove GAAP net loss and lower adjusted EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2063439000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193744,"accession_number":"0001723128-24-000037","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.","GAAP net loss $0.2M vs net income $10M in Q3 2023; diluted EPS $0.00.","Generics +9%, Specialty +19%, AvKARE +21%; launched CREXONT for Parkinson's disease.","Collaboration with Metsera for obesity/metabolic drugs; in-licensed high-value biosimilar.","Affirms full-year 2024 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2063439000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193743,"accession_number":"0001628280-24-041646","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Amneal and Metsera partner on obesity drug portfolio; new India facilities cost $150-200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amneal to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish; net cost $150-200M over 4-5 years.","Amneal named Metsera's preferred supply partner for US and Europe; licensed to commercialize in select emerging markets.","Metsera's lead candidate MET-097 (GLP-1 injectable) showed durable weight loss in Phase 1; expected first drug under collaboration.","Collaboration leverages Amneal's existing manufacturing network and provides a new high-growth vector in the obesity market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210060,"accession_number":"0001723128-24-000030","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).","Adjusted EBITDA $162M (+11% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.","Raising full-year 2024 guidance on broad-based growth across all segments.","FDA approved CREXONT (carbidopa/levodopa) for Parkinson's disease; launch expected September 2024.","Specialty revenue +7%, Generics +14% (driven by biosimilars), AvKARE +33%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1360971000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228282,"accession_number":"0001628280-24-021107","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal shareholders elect all 11 directors, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; votes ranged from 238.7M (Meister) to 254.4M (Yanai) for.","Advisory vote on NEO compensation approved with 254.4M for, 1.2M against.","Ratification of Ernst & Young as auditor for FY2024 passed with 279.1M for, 0.6M against.","Broker non-votes of ~24.1M shares on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228281,"accession_number":"0001723128-24-000018","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.","GAAP net loss $92M ($0.30 loss per share) includes $94M pre-tax charge for nationwide opioids settlement in principle.","Adjusted EBITDA $152M (+31% YoY); adjusted diluted EPS $0.14 (vs $0.12 YoY).","Opioids settlement payable over ten years; company affirming 2024 full-year guidance.","All three segments posted double-digit revenue growth for first time in same quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":659191000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}